Performance of DNLI Denali Therapeutics | -42.5% in 12m

Compare DNLI with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Denali Therapeutics with its related Sector/Index XBI

Compare Denali Therapeutics with its related Sector/Index XBI

Performance Duell DNLI vs XBI

TimeFrame DNLI XBI
1 Day -2.82% -0.83%
1 Week -3.05% 4.13%
1 Month -3.22% 6.12%
3 Months -13.81% 25.72%
6 Months -28.92% 17.87%
12 Months -42.45% 11.63%
YTD -22.67% 2.38%
Rel. Perf. 1m -0.63
Rel. Perf. 3m -4.62
Rel. Perf. 6m -4.74
Rel. Perf. 12m -6.44

What is the Fair Value of DNLI?

Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of February 2024 is 14.17. This means that DNLI is currently overvalued and has a potential downside of -14.33%.

Is Denali Therapeutics a good stock to buy?

No, based on ValueRay Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (February 2024) a stock to sell. It has a ValueRay Fundamental Rating of -6.57 and therefor a bad negative outlook.

Is DNLI a buy, sell or hold?

Denali Therapeutics has received a consensus analysts rating of 4.53. Therefor, it is recommend to buy DNLI. The Ratings are as follow, Based on 17 ratings

  • Strong Buy: 11
  • Buy: 4
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

How much will DNLI be worth in one year?

According to ValueRays Forecast Model, DNLI Denali Therapeutics will be worth about 15.8 in February 2025. The stock is currently trading at 16.54. This means that the stock has a potential downside of -4.78%.
Last Price 16.54 (Upside)
Wallstreet Target Price 47.2 185.3%
Analysts Target Price 55.6 236.2%
ValueRay Target Price 15.8 -4.8%
Values above 0%: DNLI is performing better - Values below 0%: DNLI is underperforming

Compare DNLI with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY -3.59% -6.19% -42.85% -68.82%
US NASDAQ 100 QQQ -2.76% -4.68% -46.81% -88.79%
US Dow Jones Industrial 30 DIA -3.96% -5.25% -41.90% -61.17%
German DAX 40 DBXD -4.14% -6.26% -38.13% -52.06%
UK FTSE 100 ISFU -6.37% -6.47% -35.76% -47.65%
Shanghai Shenzhen CSI 300 CSI 300 -6.96% -4.92% -13.85% -21.11%
Hongkong Hang Seng HSI -5.04% -1.34% -12.65% -19.75%
Japan Nikkei 225 EXX7 -3.54% -8.57% -47.58% -65.44%
India NIFTY 50 INDA -6.23% -7.19% -47.18% -72.02%
Brasil Bovespa EWZ -7.45% -5.43% -44.35% -69.17%
Bitcoin BTC -8.22% 0.33% -81.11% -139.93%

DNLI Denali Therapeutics vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC -3.73% -8.57% -49.81% -89.44%
Consumer Discretionary XLY -3.71% -4.62% -37.08% -65.35%
Consumer Staples XLP -4.71% -6.00% -32.49% -46.02%
Energy XLE -4.74% -8.98% -26.64% -47.04%
Financial XLF -5.09% -7.41% -46.46% -55.45%
Health Care XLV -4.64% -7.29% -38.43% -55.71%
Industrial XLI -4.55% -7.85% -40.87% -61.41%
Materials XLB -5.92% -6.58% -35.30% -51.01%
Real Estate XLRE -4.91% -2.16% -37.63% -44.61%
Technology XLK -1.94% -3.39% -48.71% -90.62%
Utilities XLU -5.10% -3.56% -27.62% -36.56%
Aerospace & Defense XAR -5.17% -7.10% -41.71% -56.55%
Biotech XBI -7.18% -9.34% -46.79% -54.08%
Homebuilder XHB -4.26% -6.23% -54.26% -92.55%
Retail XRT -4.49% -9.57% -43.26% -52.02%

DNLI Denali Therapeutics vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO -2.73% -8.45% -28.70% -51.04%
Natural Gas UNG 1.78% 25.77% 18.10% 6.34%
Gold GLD -4.64% -2.98% -35.55% -52.33%
Silver SLV -7.36% -5.16% -27.56% -47.43%
Copper CPER -7.25% -5.04% -32.99% -36.54%

Returns of DNLI vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT -3.58% -2.21% -31.21% -38.20%
iShares High Yield Corp. Bond HYG -3.70% -3.59% -36.11% -53.87%

Why you should compare the Total Return of Denali Therapeutics?

Total Returns are not just stock price changes but also Dividends and other income sources, offering a better overview of investment outcomes.
ValueRay compares the Total Return of Denali Therapeutics (last price 16.54) with its related Sector/Index XBI (SPDR S&P Biotech). Its a Technical Analysis that provides investors with a comprehensive perspective on the company's performance. This comparison allows investors to assess how DNLI Denali Therapeutics returns stack up against the performance of its broader sector, the XBI. This analysis assists investors in making well-informed decisions about their investments. It provides insights into whether Denali Therapeutics is outperforming or underperforming its sector in terms of Total Returns.

Does Denali Therapeutics outperforms the market?

No, over the last 12 months Denali Therapeutics (DNLI) made -42.45%, while its related Sector, the SPDR S&P Biotech (XBI) made 11.63%.
Over the last 3 months DNLI made -13.81%, while XBI made 25.72%.